TRHP 222

Drug Profile

TRHP 222

Alternative Names: CAT-02-106; CD22-4AP

Latest Information Update: 03 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Catalent Pharma Solutions
  • Developer Triphase Accelerator Corporation
  • Class Antineoplastics; Immunoconjugates
  • Mechanism of Action CD22 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical B cell lymphoma

Most Recent Events

  • 09 Dec 2017 Pharmacokinetics, pharmacodynamics, tolerability data from preclinical studies in B-cell lymphoma presented at 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-2017)
  • 09 Dec 2017 Triphase Accelerator Corporation plans a phase I trial for B-cell lymphoma in USA in 2018
  • 01 May 2017 Triphase Accelerator completes pre-IND and pre-CTA discussions with the United States Food and Drug Administration and Health Canada for the clinical development of CD22-4AP
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top